Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-04

Clinical Trial Update: Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia [Phase 2]

View source ↗

Summary

Phase 2 trial of IW-1701 (an sGC stimulator) in Achalasia was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IW-1701 (IW-1701)

Snippet

Sponsor: Cyclerion Therapeutics | Conditions: Achalasia | Phase 2 | Status: TERMINATED | Results posted: 2021-05-04